FWM
TXMD icon

Focused Wealth Management’s TherapeuticsMD TXMD Stock Holding History

Focused Wealth Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-16
Closed -$36 – 912
2023
Q4 		$36 Hold
16
– – ﹤0.01% 999
2023
Q3 		$48 Hold
16
– – ﹤0.01% 1008
2023
Q2 		$66 Hold
16
– – ﹤0.01% 1035
2023
Q1 		$60 Hold
16
– – ﹤0.01% 1016
2022
Q4 		$89 Hold
16
– – ﹤0.01% 1043
2022
Q3 		$0 Hold
16
– – ﹤0.01% 1062
2022
Q2 		$0 Hold
16
– – ﹤0.01% 1081
2022
Q1 		$0 Buy
16
+8
+100% +$126 ﹤0.01% 1113
2021
Q4 		$0 Hold
8
– – ﹤0.01% 1102
2021
Q3 		$0 Hold
8
– – ﹤0.01% 1109
2021
Q2 		$0 Hold
8
– – ﹤0.01% 1039
2021
Q1 		$1K Hold
8
– – ﹤0.01% 879
2020
Q4 		$0 Hold
8
– – ﹤0.01% 905
2020
Q3 		$1K Buy
8
+4
+100% +$319 ﹤0.01% 748
2020
Q2 		$0 Buy
+4
New +$233 ﹤0.01% 831

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Focused Wealth Management's TXMD Position: Q1 2024 in Review

Focused Wealth Management sold out of TherapeuticsMD (TXMD) in Q1 2024, closing a stake of 16 shares — an estimated $36 sold.

Focused Wealth Management first reported a position in TXMD in Q2 2020 and held it in 15 quarters. The position peaked at $1K in Q1 2021. 43 funds tracked by Wall St. Rank hold TXMD as of Q1 2024.

  • Focused Wealth Management reported no remaining TherapeuticsMD position as of Q1 2024 after selling out during the quarter.
  • Focused Wealth Management sold 16 TherapeuticsMD shares in Q1 2024, an estimated $36.
  • Focused Wealth Management first reported a position in TherapeuticsMD in Q2 2020 and held it in 15 quarters.
  • Focused Wealth Management's TherapeuticsMD position peaked at $1K in Q1 2021.
  • 43 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2024.

Based on Focused Wealth Management's 13F filing for Q1 2024, filed 8 May 2024.